Novel MRI assessment of treatment response in HIV-associated NAFLD: a randomized trial of an SCD1 inhibitor (ARRIVE Trial)

Aramchol, an oral stearoyl-coenzyme-A-desaturase-1 (SCD1) inhibitor, has been shown to reduce hepatic-fat content in patients with primary nonalcoholic-fatty-liver-disease (NAFLD), however, its effect in patients with HIV-associated NAFLD is unknown. The ARRIVE trial was a double-blind, randomized,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Hepatology
Main Authors: Ajmera, Veeral H., Cachay, Edward, Ramers, Christian, Vodkin, Irine, Bassirian, Shirin, Singh, Seema, Mangla, Neeraj, Bettencourt, Richele, Aldous, Jeannette L, Park, Daniel, Lee, Daniel, Blanchard, Jennifer, Mamidipalli, Adrija, Boehringer, Andrew, Aslam, Saima, Leinhard, Olof Dahlqvist, Richards, Lisa, Sirlin, Claude, Loomba, Rohit
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7164416/
https://ncbi.nlm.nih.gov/pubmed/31013363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.30674
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares